Holen Sie sich die Stockscreener-App
2.05
4.06%
0.08
Handel nachbörslich:
2.04
-0.010
-0.49%
Schlusskurs vom Vortag:
$1.97
Offen:
$1.99
24-Stunden-Volumen:
3.74M
Relative Volume:
0.51
Marktkapitalisierung:
$369.18M
Einnahmen:
$850.00K
Nettoeinkommen (Verlust:
$-68.17M
KGV:
-4.9806
EPS:
-0.4116
Netto-Cashflow:
$-53.29M
1W Leistung:
+6.77%
1M Leistung:
+10.22%
6M Leistung:
-58.67%
1J Leistung:
-6.39%
1-Tages-Spanne:
$1.985
$2.14
1-Wochen-Bereich:
$1.88
$2.14
52-Wochen-Spanne:
$1.61
$6.88
Compass Therapeutics Inc Stock (CMPX) Company Profile
Firmenname
Compass Therapeutics Inc
Sektor
Branche
Telefon
617-500-8099
Adresse
80 GUEST STREET, BOSTON
Compare CMPX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
2.05 | 367.38M | 850.00K | -68.17M | -53.29M | -0.4116 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-13 | Eingeleitet | Craig Hallum | Buy |
| 2026-01-05 | Eingeleitet | William Blair | Outperform |
| 2025-12-03 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-12-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-12-03 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-07-01 | Fortgesetzt | Raymond James | Outperform |
| 2025-04-02 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-02-24 | Eingeleitet | Guggenheim | Buy |
| 2025-02-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-23 | Eingeleitet | D. Boral Capital | Buy |
| 2024-11-15 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-16 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2023-01-31 | Eingeleitet | Jefferies | Buy |
| 2023-01-27 | Eingeleitet | Stifel | Buy |
| 2022-05-23 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-03-15 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2022-01-19 | Eingeleitet | B. Riley Securities | Buy |
| 2021-12-22 | Eingeleitet | Raymond James | Outperform |
| 2021-12-20 | Eingeleitet | SVB Leerink | Outperform |
| 2021-12-15 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Compass Therapeutics Inc Aktie (CMPX) Neueste Nachrichten
Compass Therapeutics eyes FDA path after Tovecimig trial win - MSN
Compass Therapeutics (NASDAQ: CMPX) investors back board, auditor and pay in 2026 votes - Stock Titan
CMPX: Lead oncology asset tovecimig nears FDA filing after strong BTC trial results; multiple catalysts ahead - TradingView
Compass Therapeutics, Inc. (CMPX) Latest Stock News & Headlines - Yahoo Finance
Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win - MarketBeat
CMPX News | COMPASS THERAPEUTICS INC (NASDAQ:CMPX) - ChartMill
Citizens reiterates Compass Therapeutics stock rating on ASCO data By Investing.com - Investing.com Nigeria
CMPX Stock Chart | COMPASS THERAPEUTICS INC (NASDAQ:CMPX) - ChartMill
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Compass Therapeutics (CMPX) and Tenax Therapeutics (TENX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Emergent Biosolutions (EBS) and Compass Therapeutics (CMPX) - The Globe and Mail
Piper Sandler Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
Stifel reiterates Compass Therapeutics stock rating on ASCO data By Investing.com - Investing.com Canada
Number of shareholders of Compass Therapeutics, Inc. – NASDAQ:CMPX - TradingView
CMPX Q1 2026 Earnings: Narrow EPS Beat Drives Positive Stock ReactionTrough Earnings Signal - thelegaladvocate.com
Compass Therapeutics to Participate in Upcoming June Investor Events - Investing News Network
Biotech Compass Therapeutics to present at Jefferies and Goldman Sachs events - Stock Titan
Compass Therapeutics (CMPX) Breaks Above Support: What’s Driving the 4.6% MoveStrangle Setup - newsline.com
CMPX Q1 2026 Earnings: Narrowed Loss Beats Estimates, Stock Surges 7.25%Forward Guidance Trends - newsline.com
Compass Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Supports Biotech’s Pipeline ProgressNegative Surprise Momentum - newsline.com
Compass Therapeutics reports phase 1 data for CTX-8371 By Investing.com - Investing.com South Africa
Compass Therapeutics reports phase 1 data for CTX-8371 - Investing.com UK
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting - Investing News Network
Compass Therapeutics Announces Promising Phase 1 Results for CTX-8371, Innovative Dual Checkpoint Blocker in Advanced Malignancies - Quiver Quantitative
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc.CMPX - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass ... - Caledonian Record
CMPX: Lead bispecific antibody shows strong efficacy in BTC; FDA submission and pipeline advances ahead - TradingView
Compass Therapeutics (CMPX) Reports Q1 2026 Net Loss of $18.3M - Yahoo Finance
Compass Therapeutics (CMPX) price target decreased by 26.39% to 10.11 - MSN
5 Best NASDAQ Stocks Under $5 to Buy Right Now - Insider Monkey
Compass Therapeutics(CMPX) Stock Options Chain | Quotes & News - Moomoo
Compass Therapeutics’s stock crashes after OS miss in BTC trial - MSN
Bronstein, Gewirtz & Grossman, LLC Is Investigating Compass Thera - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Compass Therapeutics, Inc. (CMPX) And Encourages Shareholders to Reach Out - ACCESS Newswire
2026-05-13 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Compass Therapeutics, Inc. (CMPX) And Encourages Shareholders to Reach Out | NDAQ:CMPX | Press Release - Stockhouse
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - FinancialContent
TradingKey - TradingKey
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Compass Therapeutics, Inc. (CMPX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
2026-05-12 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Compass Therapeutics, Inc. (CMPX) and Encourages Shareholders to Learn More About the Investigation | NDAQ:CMPX | Press Release - Stockhouse
Compass Therapeutics to Participate in Upcoming May Investor Events - The Manila Times
Compass Therapeutics, Inc. (CMPX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Compass Therapeutics, Inc. (CMPX) Investigation: Bronstein, Gewir - The National Law Review
CMPX (Compass Tx) shares surge 3% as biotech firm essentially meets Q1 loss expectations.Trader Community Insights - newser.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Compass Therapeutics, Inc. (CMPX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
LifeSci Capital Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Finanzdaten der Compass Therapeutics Inc-Aktie (CMPX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.60%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):